Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 12, 2019

View Archived Issues

Targeting lymph node stage may nip metastases in the bud

Genome editing used to create models of GM1-gangliosidosis and Morquio syndrome type B

Free radicals can benefit the brain

Urethral macrophages are HIV reservoir

Xiamen University describes triggering receptor expressed on myeloid cells 2 polypeptides

Rho-associated protein kinase 1/2 inhibitors disclosed by Kadmon

Curigin patents nucleic acid molecules inhibiting MTOR and AR gene expression

Beijing Sanyou Liheze Biological Technology describes anticoagulant fusion protein

HDAC3 is a novel therapeutic target for ischemic stroke

Results presented from phase I/II CHAMPIONS study of SB-913

New biomarkers discovered tied to intracranial aneurysm

ADAR1-editing of cell-cycle-regulatory miRNAs is involved in progenitor malignant transformation

Tumor-specific near-infrared agent targeting PSMA for fluorescence-guided surgery in prostate cancer

Sterol regulatory element binding protein as a potential target for broad-spectrum antiviral agents

Viral-mediated TMBIM6 gene delivery protects against neonatal hypoxic ischemia

European Commission extends marketing authorization for Adcetris

Sprycel receives European approval in pediatric patients with newly diagnosed Ph+ ALL

Patient enrollment ongoing in phase I study of SER-401 in combination with nivolumab

FDA approves IND for ABBV-0805 for Parkinson's disease

Ascendis announces phase II trial of TransCon PTH to treat hypoparathyroidism

Increased miR-9 levels in CSF found to be a poor prognostic factor after subarachnoid hemorrhage

Bicycle awarded contract to identify novel inhibitors of PBPs of key bacterial pathogens

3SBio and Verseau collaborate in immuno-oncology

STELLAR-4 trial of selonsertib in compensated cirrhosis due to NASH does not meet week 48 endpoint

Redx's preclinical ROCK-II compound suppresses collagen deposition and pathways linked to fibrosis

Aduro doses first patient with ADU-S100 and Yervoy for melanoma in phase I trial

New phase III trial in China studies HC-1119 for metastatic CRPC